Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.
Drug Discov Today. 2021 Aug;26(8):1991-2002. doi: 10.1016/j.drudis.2021.04.025. Epub 2021 May 5.
Alzheimer's disease (AD) is an irreversible neurodegenerative brain disorder which manifests as a progressive decline in cognitive function. Mitochondrial dysfunction plays a critical role in the early stages of AD, and advances the progression of this age-related neurodegenerative disorder. Therefore, it can be a potential target for interventions to treat AD. Several therapeutic strategies to target mitochondrial dysfunction have gained significant attention in the preclinical stage, but the clinical trials performed to date have shown little progress. Thus, we discuss the mechanisms and strategies of different therapeutic agents for targeting mitochondrial dysfunction in AD. We hope that this review will inspire and guide the development of efficient AD drugs in the future.
阿尔茨海默病(AD)是一种不可逆转的神经退行性脑疾病,表现为认知功能的进行性下降。线粒体功能障碍在 AD 的早期阶段起着关键作用,并推进了这种与年龄相关的神经退行性疾病的进展。因此,它可能成为治疗 AD 的干预措施的潜在靶点。几种针对线粒体功能障碍的治疗策略在临床前阶段引起了广泛关注,但迄今为止进行的临床试验进展甚微。因此,我们讨论了针对 AD 中线粒体功能障碍的不同治疗药物的作用机制和策略。我们希望本综述能够为未来高效 AD 药物的开发提供启示和指导。